Download as PDF
PreveCeutical Issued Statement Regarding Promotional Activity
Vancouver, British Columbia: PreveCeutical Medical Inc. (“PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H) provides the following information about certain promotional activities at the request of OTC Markets.
On June 15, 2020, the Company was notified by OTC Markets that recently, certain materials promoting PreveCeutical’s common stock were circulated via email by a third party. Copies of the promotional emails were forwarded to PreveCeutical’s CFO by OTC Markets. The Company immediately confirmed to OTC Markets that it had no prior knowledge of this unauthorized promotional activity and had only been made aware of such activity pursuant to the OTC Markets notice. There was an increase in trading volume with a minor increase in share value.
To our knowledge, the Company’s management, officers, directors, any controlling shareholders (defined as shareholders owning 10% or more of the Company’s securities), or any third-party service providers have not directly or indirectly been involved in any way (including payment of a third-party) with the creation, distribution, or payment of promotional materials related to the Company and its security.
Content provided about PreveCeutical’s programs made in the promotional statements seems to be taken from our website and prior news releases. Any comments related to PreveCeutical’s program do not appear to be misleading.
PreveCeutical inquired with all managers, officers, directors, controlling shareholders, and current third-party service providers, that they have not sold Company stock at any time within the past 90 days.
The Companies has engaged the following third-party providers to provide investor relations services, public relations services, marketing, and other related services, including the promotion of the Company or its securities in the last twelve months:
Proactive Investors (September 2018 to August 2019)
Streetwise Investors Club (May 2019 to August 2019)
Follow the Money Investor (February 2019 to August 2019)
The Company has not issued shares or convertible instruments allowing conversion to equity securities at prices constituting a discount to the current market rate at the time of the issuance.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences. The Company’s current research and development programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders; Nature Identical™ peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.
On behalf of the Board of Directors of PreveCeutical
Stephen Van Deventer, Chairman and Chief Executive Officer
For further information, please contact:
Stephen Van Deventer at telephone: +1 604 306 9669
Or, Investor Relations email@example.com
This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans and expectations regarding the future, including, without limitation, the anticipated business plans and timing of future business activities of the Company. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company’s Canadian continuous disclosure filings are available at www.sedar.com.
Readers are cautioned not to put undue reliance on forward-looking statements. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements.